Corvus Pharmaceuticals (CRVS) Accumulated Expenses (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Accumulated Expenses of $1.4 million for Q1 2026, down 64.32% year-over-year from $3.9 million in Q1 2025, and down 78.71% quarter-over-quarter from $6.5 million in Q4 2025.
Corvus Pharmaceuticals (CRVS) Accumulated Expenses (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 64.32% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (down 64.32% YoY), while the FY2025 annual figure was $6.5 million, up 74.12% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $1.4 million, down from $6.5 million in the prior quarter.
- The five-year high for Accumulated Expenses was $8.6 million in Q3 2022, with the low at $589000.0 in Q1 2024.
- The 5-year median for Accumulated Expenses is $4.2 million (2024), against an average of $3.8 million.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 89.52% in 2024, then jumped 557.22% in 2025.
- Corvus Pharmaceuticals' Accumulated Expenses stood at $1.1 million in 2022, then tumbled by 38.54% to $684000.0 in 2023, then surged by 444.59% to $3.7 million in 2024, then jumped by 74.12% to $6.5 million in 2025, then slumped by 78.71% to $1.4 million in 2026.
- Business Quant data shows CRVS's Accumulated Expenses at $1.4 million in Q1 2026, $6.5 million in Q4 2025, and $715000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.17 Mn |
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | 6.49 Mn |
| Sep 30, 2025 | 715,000.00 |
| Jun 30, 2025 | 5.01 Mn |
| Mar 31, 2025 | 3.87 Mn |
| Dec 31, 2024 | 3.73 Mn |
| Sep 30, 2024 | 4.22 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 589,000.00 |
| Dec 31, 2023 | 684,000.00 |
| Sep 30, 2023 | 4.56 Mn |
| Jun 30, 2023 | 804,000.00 |
| Mar 31, 2023 | 5.62 Mn |
| Dec 31, 2022 | 1.11 Mn |
| Sep 30, 2022 | 8.57 Mn |
| Jun 30, 2022 | 6.37 Mn |
| Mar 31, 2022 | 5.99 Mn |
| Dec 31, 2021 | 1.85 Mn |
| Sep 30, 2021 | 1.41 Mn |